NIH’s All of Us program launches BYOD project: Another use case for future trials

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/pressureUA)
(Image: Getty/pressureUA)

Related tags: Thread, Nih, Precision medicine, Wearables, mHealth, Pharmacogenomics, BYOD, Digital

The All of Us research program is expanding its data collection abilities via Fitbit – a move that further demonstrates the industry’s increasing adoption of a BYOD approach, says Thread executive.

The National Institutes of Health’s (NIH) program, part of the Precision Medicine Initiative (PMI) which launched in 2016​, aims to enroll more than one million US participants by 2020.

The study is not focusing on a specific disease. Instead, researchers hope to create a platform to enable trials of targeted therapies and to gain a better understanding of the use of mobile health (mHealth), among other goals.

Read: Million-person precision medicine study 'a constant learning process'

In line with this, the All of Us research program this week launched​ the Fitbit bring-your-own-device (BYOD) project – a “key step”​ in the program’s goal to integrate digital technology.

Participants now will be able to share data from their Fitbit accounts, in addition to providing information through surveys, electronic health records (EHRs), and biosamples.

NIH is planning to further incorporate digital health technologies in the program with a second Fitbit project slated to launch later this year. This will include providing devices to a select number of All of Us participants who will be randomly invited to participate.

According to the NIH, the program will add connections to additional devices and applications in the future.

Continuing BYOD momentum

John Reites, chief product officer and partner at Thread​, said the announcement is yet another example of the continued momentum toward standard use of BYOD mobile and wearables for research.

We are not only seeing this approach used in post-approval research and registries but also Phase II/III studies,”​ he told us, noting the several advantages to a BYOD approach, including increased insights with built-in patient engagement at lower costs.

“The challenges our industry is still working through for broader adoption of a BYOD wearable approach is that not everyone owns a wearable device, not everyone will opt-in/consent to donate their data and the outcomes gathered will likely support exploratory endpoints at first,” ​Reites explained.

However, today’s studies using this approach will help address these challenges, defining additional use cases for the future, ​he said.

“It’s great to see the All of Us Research Program and Fitbit team moving this innovative approach forward,”​ Reites added. “Examples like this study are enabling life science organizations to strongly consider BYOD wearable approaches for their studies.”

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars